Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Constance CareWAR:CCR 20 EV-to-EBITDA is 521.89 as of Aug. 14, 2026, which is 2290% above its 10-year median of 21.84. GuruFocus rates WAR:CCR with a GF Score™ of 20/100 and a GF Value™ of zł0.15 (Significantly Overvalued). Among 511 Healthcare Providers & Services companies, Constance Care ranks worse than 99.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Constance Care's enterprise value is zł18.79 Mil.
Constance Care's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.04 Mil. Therefore, Constance Care's EV-to-EBITDA for today is 521.89.
The historical rank and industry rank for Constance Care's EV-to-EBITDA or its related term are showing as below:
WAR:CCR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -187.15 Med: 21.84 Max: 524.08
Current: 521.89
During the past 6 years, the highest EV-to-EBITDA of Constance Care was 524.08. The lowest was -187.15. And the median was 21.84.
WAR:CCR's EV-to-EBITDA is ranked worse than 99.22% of 511
companies
in the Healthcare Providers & Services industry
Industry Median: 10.76
vs WAR:CCR: 521.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Constance Care's PE Ratio (TTM) for today is calculated as:
Constance Care's share price for today is zł5.10.
Constance Care's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.601.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Constance Care's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Constance Care's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Constance Care EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Constance Care's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Constance Care's EV-to-EBITDA falls into.
Constance Care's current Enterprise Value is zł18.79 Mil.
Constance Care's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Constance Care (WAR:CCR) has a EV-to-EBITDA of 521.89 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Constance Care. This is 2290% above median its historical median of 21.84. According to the industry distribution chart, Constance Care ranks #507 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 99.2%.
Is Constance Care's EV-to-EBITDA too high?
Constance Care's current EV-to-EBITDA of 521.89 is 2290% above median its 10-year median of 21.84. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.76. Constance Care's value of 521.89 is 4750.3% above this industry median. Based on the distribution chart, Constance Care ranks #507 out of 511 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Constance Care has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Constance Care's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Constance Care ranks #507 out of 511 companies for EV-to-EBITDA. This places Constance Care in the lower half of its industry. The industry median EV-to-EBITDA is 10.76. Constance Care's value of 521.89 is 4750.3% above this benchmark. While the company's 10-year median is 21.84 vs. the industry median of 10.76, Constance Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.76, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Constance Care's current EV-to-EBITDA of 521.89 is 4750.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Constance Care. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Constance Care's current EV-to-EBITDA is 521.89, which is 2290% above median its own 10-year median of 21.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Constance Care stock overvalued right now?
Based on GuruFocus' analysis, Constance Care (WAR:CCR) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.15, compared to a current price of zł5.10 — trading 3300% above its estimated fair value. The current EV-to-EBITDA is 521.89, which is 2290% above median its 10-year median of 21.84 and 4750.3% above the Healthcare Providers & Services industry median of 10.76. Constance Care's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Constance Care (WAR:CCR), the current EV-to-EBITDA is 521.89 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Constance Care (WAR:CCR) Overvalued in 2026?
Based on GuruFocus' analysis, Constance Care stock appears to be overvalued.
The current stock price of zł5.10 is trading 3300% above its estimated GF Value™ of zł0.15.
GuruFocus considers Constance Care to be Significantly Overvalued.
Key valuation signals for WAR:CCR:
EV-to-EBITDA: 521.89 (2290% above median its 10-year median of 21.84)
GF Value™: zł0.15 vs. price of zł5.10 (3300% above fair value)
Industry Position: 4750.3% above the Healthcare Providers & Services median (#507 of 511)
No single metric tells the full story. See the WAR:CCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Constance Care SA conducts physiotherapeutic activities aimed at improving the quality of health and life of people suffering both from musculoskeletal disorders as a result of various random events, diseases or related to the aging of the body, as well as the rehabilitation of cognitive functions in children and adults.
20GF Score
Get the complete analysis for WAR:CCR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CCR has been successfully added to your 
